Surgery – Cardiac augmentation
Reexamination Certificate
2000-07-10
2001-08-28
Evanisko, George R. (Department: 3762)
Surgery
Cardiac augmentation
C623S003130
Reexamination Certificate
active
06280377
ABSTRACT:
BACKGROUND OF THE INVENTION
The present invention deals with treatment of heart disease. More particularly, the present invention deals with a system and method for treating heart disease by regulating blood flow in the vasculature.
Congestive heart failure is a common heart disease. The prevalence of incidents of congestive heart failure has recently increased, and there is considerable morbidity and mortality-associated with its diagnosis. In fact, congestive heart failure is an extremely lethal disease with an estimated five year mortality for a vast majority of both men and women who encounter the disease.
Congestive heart failure results from loss of, or impairment of, normal heart function. This loss or impairment reduces cardiac output. This, in turn, results in a reduction in both blood. flow and blood pressure in the kidneys. This reduction in flow and pressure causes a renin-angiotensin response that exacerbates congestive heart failure.
Briefly, as blood flow and pressure is reduced in the kidneys, cells in the kidneys referred to as juxtaglomerular apparatus secret an enzyme referred to as renin into the blood. The enzyme renin cleaves a ten-amino acid polypeptide called angiotensin I from a plasma protein in the blood called angiotensinogen. A converting enzyme in the blood removes two amino acids from the angiotensin I polypeptide leaving an eight amino acid polypeptide called angiotensin II. Angiotensin II has numerous effects on the smooth muscle layers of arterioles, including causing vasoconstriction. Further, an indirect effect of an increase in angiotensin II increases blood volume. Blood volume is increased because angiotensin II stimulates secretion of aldosterone from the adrenal cortex which, in turn, causes an increase in salt and water retention in the kidneys. Angiotensin II also stimulates thirst centers in the hypothalamus causing more water to be ingested. The increase in blood volume and the corresponding vasoconstriction cause an increase in blood pressure and hence a volume overload on the heart which causes further deterioration of the heart condition.
Another response is also related to congestive heart failure. Baroreceptors, referred to as stretch receptors, reside in the aortic arch and carotid sinuses. The baroreceptors are essentially pressure sensors sensing blood pressure in that area. The baroreceptors provide physiological feedback in two ways. First, in response to a reduction in blood pressure, the baroreceptors provide a neurohormonal feedback response which acts to increase the heart rate in an attempt to increase cardiac output. The increased heart rate causes the heart to work harder which, in turn, causes the heart muscle to stretch further. Also, a reduction in pressure caused by a reduction in cardiac output causes the baroreceptors to provide a feedback response which acts to constrict the distal vasculature thus increasing pressure in that area.
It can thus be seen that impairment of heart function can lead to a cyclical feedback response which increases, rather than reduces, the impairment. Such a cyclical feedback response is sometimes referred to as a cascade.
For instance, if the heart muscle is stressed, the heart works harder and begins to stretch. This reduces the efficiency of the heart. This inefficient or impaired heart function causes blood pressure in the areas of both the kidneys and the baroreceptors to decrease. The feedback response generated by the kidneys causes further overload and stress on the heart. The feedback response generated by the baroreceptors causes increased heart rate. Both of these feedback responses cause the heart to work harder, causing further stretching of the heart muscle and thus leading to greater inefficiencies. In response, the feedback responses become even more acute—and the cascade continues.
SUMMARY OF THE INVENTION
A system is provided for regulating blood flow to a portion of the vasculature, such as the renal system, in order to treat heart disease. A regulator maintains blood flow so as to control physiological feedback responses in order to relieve overload conditions on the heart.
In one embodiment, a system is provided for treating heart disease in a mammal having a heart, an ascending aorta, a descending aorta, and a renal system including renal arteries. The system includes a first regulator disposed in the ascending aorta and having an inflow end and an outflow end. The first regulator receives blood flow at a first velocity of the inflow end and provides blood flow at a second velocity through the outflow end thereof, wherein the second velocity is lower than the first velocity. A second regulator is disposed in the descending aorta upstream of the renal arteries. The second regulator has an inflow end and an outflow end and receives blood flow at a third velocity at the inflow end and provides blood flow at a fourth velocity through the outflow end thereof. The fourth velocity is greater than the third velocity.
In a second embodiment, a plurality of expandable members are placed across the renal arteries and/or baroreceptors to maintain blood flow and pressure to the renal arteries and/or baroreceptors and to thus inhibit undesirable responses from the renin-angiotensin system.
REFERENCES:
patent: 3455298 (1969-07-01), Anstadt
patent: 3791374 (1974-02-01), Guarino
patent: 4407271 (1983-10-01), Schiff
patent: 4536893 (1985-08-01), Parravicini
patent: 4685446 (1987-08-01), Choy
patent: 4781716 (1988-11-01), Richelsoph
patent: 4817586 (1989-04-01), Wampler
patent: 4834707 (1989-05-01), Evans
patent: 4846831 (1989-07-01), Skillin
patent: 4861330 (1989-08-01), Voss
patent: 4863461 (1989-09-01), Jarvik
patent: 4888011 (1989-12-01), Kung et al.
patent: 4902291 (1990-02-01), Kolff
patent: 4906229 (1990-03-01), Wampler
patent: 4919647 (1990-04-01), Nash
patent: 4925377 (1990-05-01), Inacia et al.
patent: 4925443 (1990-05-01), Heilman et al.
patent: 4938766 (1990-07-01), Jarvik
patent: 4957477 (1990-09-01), Lundback
patent: 4964864 (1990-10-01), Summers et al.
patent: 5067960 (1991-11-01), Grandjean
patent: 5069680 (1991-12-01), Grandjean
patent: 5089019 (1992-02-01), Grandjean
patent: 5098442 (1992-03-01), Grandjean
patent: 5119804 (1992-06-01), Anstadt
patent: 5131905 (1992-07-01), Grooters
patent: 5167628 (1992-12-01), Boyles
patent: 5205810 (1993-04-01), Guiraudon et al.
patent: 5290227 (1994-03-01), Pasque
patent: 5308319 (1994-05-01), Ide et al.
patent: 5308320 (1994-05-01), Safar et al.
patent: 5326374 (1994-07-01), Ilbawi et al.
patent: 5332403 (1994-07-01), Kolff
patent: 5358519 (1994-10-01), Grandjean
patent: 5364337 (1994-11-01), Guiraudon
patent: 5383840 (1995-01-01), Heilman et al.
patent: 5405383 (1995-04-01), Barr
patent: 5429584 (1995-07-01), Chiu
patent: 5484385 (1996-01-01), Rishton
patent: 5505701 (1996-04-01), Anaya Fernandes de Lomana
patent: 5558617 (1996-09-01), Heliman et al.
patent: 5702343 (1997-12-01), Alferness
patent: 5733779 (1998-03-01), Horiguchi
patent: 5776190 (1998-07-01), Jarvik
patent: 5921913 (1999-07-01), Siess
patent: 0 654 283 A1 (1994-11-01), None
patent: WO 98/17347 (1998-04-01), None
“Mechanisms of Contraction”,Human Physiology, Fourth Edition, by Stuart Ira Fox, pp. 300-323.
“The Management of Chronic Heart Failure”, by Jay N. Cohn, M.D.,The New England Journal of Medicine, pp. 490-498, Aug. 15, 1996.
“Reversal of Chronic Ventricular Dilation in Patients with End-Stage Cardiomyopathy by Prolonged Mechanical Uploading”, by Howard R. Levin, M.D. et al., pp. 2717-2718, vol. 91, No. 11, Jun. 1, 1995.
“The Nature of the Atrial Receptors Responsible for a Reflex Decrease in Activity in Renal Nerves in the Dog”, by R.J. Linden, D.A.S.G. Mary and D. Weatherill,The Physiological Society, 1980, pp. 31-40.
“Control of Sympathetic Nerve Activity by Vagal Mechanoreflexes is Blunted in Heart Failure”, by Mark E. Dibner-Dunlap, M.D. and Marc D. Thames, M.D., vol. 86, No. 6, Dec. 1992, pp. 1929-1934.
“Baroreflex Regulation of Regional Blood Flow in Congestive Heart Failure”, by Mark A. Creager et al.,The American Physiological Society, 1990,
Evanisko George R.
Sci-Med Life Systems, Inc.
Westman Champlin & Kelly P.A.
LandOfFree
System for treating congestive heart failure does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with System for treating congestive heart failure, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and System for treating congestive heart failure will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2485200